Coyle et al., “Applied Biophysical Methods in Fragment-Based Drug Discovery”; SLAS DISCOVERY, 2020

Coyle et al., “Applied Biophysical Methods in Fragment-Based Drug Discovery”; SLAS DISCOVERY, 2020

https://journals.sagepub.com/doi/full/10.1177/2472555220916168?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Osbourne et al., “Fragments: where are we now?”; Biochemical Society Transactions, 2020

Osbourne et al., “Fragments: where are we now?”; Biochemical Society Transactions, 2020
https://portlandpress.com/biochemsoctrans/article-abstract/48/1/271/221949/Fragments-where-are-we-now?redirectedFrom=fulltext

Saur et al. “Fragment-based drug discovery using cryo-EM”, Drug Discovery Today, 2019

Saur et al. “Fragment-based drug discovery using cryo-EM“, Drug Discovery Today, 2019
https://www.sciencedirect.com/science/article/pii/S1359644619304659?viewFullText=true

Kidger et al. “Dual-mechanism ERK1/2 inhibitors exploit a distinct binding mode to block phosphorylation and nuclear accumulation of ERK1/2”, Molecular Cancer Therapeutics, 2019

Kidger et al., “Dual-mechanism ERK1/2 inhibitors exploit a distinct binding mode to block phosphorylation and nuclear accumulation of ERK1/2“, Molecular Cancer Therapeutics, 2019
https://mct.aacrjournals.org/content/early/2019/11/20/1535-7163.MCT-19-0505

Mortenson et al., “Fragment-to-Lead Medicinal Chemistry Publications in 2017”, Journal of Medicinal Chemistry, 2019

Mortenson et al., “Fragment-to-Lead Medicinal Chemistry Publications in 2017“, Journal of Medicinal Chemistry, 2019
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01472

Rathi et al., “Practical High-Quality Electrostatic Potential Surfaces for Drug Discovery Using a Graph-Convolutional Deep Neural Network”; Journal of Medicinal Chemistry, 2019

Rathi et al., “Practical High-Quality Electrostatic Potential Surfaces for Drug Discovery Using a Graph-Convolutional Deep Neural Network”, Journal of Medicinal Chemistry, 2019; https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01129

Murray et al., “A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA”; MedChemComm, 2019

Murray et al., “A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA”, MedChemComm, 2019; https://pubs.rsc.org/en/content/articlepdf/2019/MD/C9MD90044F

Heightman et al., “Structure–Activity and Structure–Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein–Protein Interaction.” J. Med. Chem., 2019; DOI: 10.1021/acs.jmedchem.9b00279

Heightman et al., “Structure–Activity and Structure–Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein–Protein Interaction.” J. Med. Chem., 2019; DOI: 10.1021/acs.jmedchem.9b00279

Deaton et al., “The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.” Bioorganic & Medicinal Chemistry, 2019; doi.org/10.1016/j.bmc.2019.02.017

Deaton et al., “The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.” Bioorganic & Medicinal Chemistry, 2019; doi.org/10.1016/j.bmc.2019.02.017

O’Reilly et al., “Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design.” Drug Discovery Today, 2019; doi.org/10.1016/j.drudis.2019.03.009

O’Reilly et al., “Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design.” Drug Discovery Today, 2019; doi.org/10.1016/j.drudis.2019.03.009